This is a purely administrative filing with no change to the offering terms. Monitor for the final prospectus (424B) which will set the actual offering price and confirm the effective date. The stock's $7M market cap and assumed $3.00 offering price imply significant dilution — watch for pricing updates and investor demand signals.
Executive Summary
Regentis Biomaterials Ltd. filed Amendment No. 1 to its F-1 registration statement solely to update Exhibit 23.1 (consent of independent auditor) and the exhibit index. The prospectus (Part I) is unchanged. The company is proceeding with a firm-commitment offering of 3,333,334 ordinary shares at an assumed price of $3.00 per share, with ThinkEquity LLC as underwriter. This is a routine administrative amendment that does not alter the offering terms or business disclosure.
Key Financial Metrics
Key Facts
- Amendment No. 1 to F-1 filed solely to update Exhibit 23.1 (auditor consent) and exhibit index; Part I prospectus unchanged
- Firm-commitment offering of 3,333,334 ordinary shares at assumed $3.00/share (based on April 28, 2026 closing price)
- Underwriter: ThinkEquity LLC; 45-day option to purchase additional shares (amount not specified)
- Company is an Israeli emerging growth company and foreign private issuer; shares trade on NYSE American under RGNT
- Prior F-1 filed May 1, 2026; this amendment does not modify offering terms
Financial Impact
Offering size: 3,333,334 shares at assumed $3.00/share = approximately $10M gross proceeds before underwriting discounts and expenses
Risk Factors
- Dilution risk: offering of 3.33M shares against current market cap of $7M implies substantial shareholder dilution
- Execution risk: small-cap Israeli biotech IPO with ThinkEquity as sole underwriter may face pricing or demand challenges
- Pre-revenue company with no disclosed revenue or profitability in filing documents
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| F-1/A Filing (Primary) | 0001213900-26-066555 |
| Document: ea029406901ex23-1.htm | 0001213900-26-066555 |
| Document: 0001213900-26-066555-index-headers.html | 0001213900-26-066555 |
| Document: 0001213900-26-066555-index.html | 0001213900-26-066555 |
| Document: 0001213900-26-066555.txt | 0001213900-26-066555 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | 6-K | $1.63 | awaiting T+20 | — | $1.28 (−21.23%) |
Sep 23, 2026 4w ago | EFFECT | $2.10 $1.49 | ▼ −29.05% | ▼ −29.74% | $1.28 (−39.05%) |
Jul 20, 2026 14w ago | 6-K | $2.00 $2.04 | ▲ +2.00% | ▼ −2.12% | $1.28 (−36.00%) |
Jul 15, 2026 14w ago | 6-K | $2.43 $1.94 | ▼ −20.16% | ▼ −22.51% | $1.28 (−47.33%) |
Jul 14, 2026 15w ago | EFFECT | $2.54 $1.84 | ▼ −27.56% | ▼ −30.05% | $1.28 (−49.61%) |
Jun 15, 2026 19w ago | 6-K | $9.40 $2.43 | ▲ +74.15% | ▲ +74.15% | $1.28 (+86.38%) |
Jun 9, 2026 20w ago | F-1/A | $2.41 $3.64 | ▲ +51.04% | ▲ +49.59% | $1.28 (−46.89%) |
Jun 8, 2026 20w ago | 6-K | $1.28 $3.58 | ▲ +179.69% | ▲ +178.85% | $1.28 (−0.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers